An unfavorable ruling by a judge has scuttled an agreement in which Eli Lilly would have capped insulin prices and paid $13.5 million to resolve claims that it had inflated the drug's cost.

Lawyers for a proposed nationwide class of individuals, who paid for Lilly's Humalog injection and other insulin drugs, said in a filing in Newark, N.J. federal court that they and Lilly had decided not to go forward seeking approval for the deal.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.